Literature DB >> 15858710

Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS).

T Langer1, W Stöhr, M Paulides, A Kremers, H-G Dörr, U Göbel, J D Beck.   

Abstract

BACKGROUND: Late effects become progressively more important for the evaluation of therapeutic success in paediatric oncology. Thus, in 1998, the Late Effects Surveillance System (LESS) started to register and assess multicentrally, prospectively and longitudinally late effects of treatment for the group of Ewing's, soft tissue- and osteosarcoma patients. PATIENTS AND METHODS: The yearly results of the follow-up examinations of 785 Ewing's, soft tissue- and osteosarcoma patients, who were treated from 1.1.1998 until 31.12.2001, were prompted and assessed conforming to the guidelines developed by the LESS-study.
RESULTS: 136/181 (75 %) of follow-up institutions take part in the LESS-study. Only 8 % of patients eligible for the LESS-study were cared for in non-cooperating facilities. Questionnaire return could be raised to 73-78 % and data completeness could also be significantly improved in the course of the study. Departments of internal medicine had a lower questionnaire return percentage than departments of paediatrics. Data availability for the nephrologic after-care was not satisfactory.
CONCLUSIONS: The LESS project has been well established. Thus, the basis has been set for the development of risk-oriented strategies for intervention and for the further improvement of the follow-up of major late effects in sarcoma patients.

Entities:  

Mesh:

Year:  2005        PMID: 15858710     DOI: 10.1055/s-2005-836503

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  6 in total

1.  Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).

Authors:  W Stöhr; M Paulides; I Brecht; A Kremers; J Treuner; T Langer; J D Beck
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-05       Impact factor: 4.553

Review 2.  Current strategies of chemotherapy in osteosarcoma.

Authors:  Dorothe Carrle; Stefan S Bielack
Journal:  Int Orthop       Date:  2006-08-03       Impact factor: 3.075

3.  UK Guidelines for the Management of Bone Sarcomas.

Authors:  Robert Grimer; Nick Athanasou; Craig Gerrand; Ian Judson; Ian Lewis; Bruce Morland; David Peake; Beatrice Seddon; Jeremy Whelan
Journal:  Sarcoma       Date:  2010-12-29

4.  Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients.

Authors:  Alexandra Nitz; Evangelos Kontopantelis; Stefan Bielack; Ewa Koscielniak; Thomas Klingebiel; Thorsten Langer; Marios Paulides
Journal:  Oncol Lett       Date:  2012-10-25       Impact factor: 2.967

Review 5.  UK guidelines for the management of bone sarcomas.

Authors:  Craig Gerrand; Nick Athanasou; Bernadette Brennan; Robert Grimer; Ian Judson; Bruce Morland; David Peake; Beatrice Seddon; Jeremy Whelan
Journal:  Clin Sarcoma Res       Date:  2016-05-04

6.  Combination of electroporation delivered metabolic modulators with low-dose chemotherapy in osteosarcoma.

Authors:  Kheshwant S Gill; Philana Fernandes; Brian Bird; Declan M Soden; Patrick F Forde
Journal:  Oncotarget       Date:  2018-07-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.